Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Gerardo Rosati's publication output changed over time?
ScholarIQpublication output · 2007–2023
Output grew0% over the shown period — from 1 works in 2007 to 1 in 2023.
1
2
1
1
1
1
2
1
1
200720092011201420152018201920212023
What are the most-cited papers on Gerardo Rosati?
ScholarIQmost cited works
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
C. Aschele, L. Cionini, Sara Lonardi, Carmine Pinto, Stefano Cordio, Gerardo Rosati, Salvatore Artale, A. Tagliagambe, Giovanni Ambrosini, Paola Rosetti, Andrea Bonetti, Maria Emanuela Negru, Maria Chiara Tronconi, Gabriele Luppi, Giovanni Silvano, Domenico Corsi, Anna Maria Bochicchio, Germana Chiaulon, Maurizio Gallo, Luca Boni
Journal of Clinical Oncology. 2011769 CitationsOPEN ACCESS
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
Gerardo Rosati, G. Ambrosini, Sandro Barni, B. Andreoni, G Corradini, Giovanna Luchena, Bruno Daniele, Fernando Gaion, Giovanni William Oliverio, Mary Duro, G. Martignoni, N. Pinna, Pietro Sozzi, G. Pancera, Gaspare Solina, Gianfranco Pavia, Sandro Pignata, F. Bing Johnson, Roberto Labianca, Giovanni Apolone, Alberto Zaniboni, Marta Monteforte, Eva Negri, Valter Torri, Paola Mosconi, Roldano Fossati
Annals of Oncology. 2015136 CitationsOPEN ACCESS
Lapatinib in breast cancer
Domenico Bilancia, Gerardo Rosati, Angelo Dinota, Domenico Germano, Rosangela Romano, Luigi Manzione
Annals of Oncology. 2007129 CitationsOPEN ACCESS
Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
C. Aschele, Carmine Pinto, Stefano Cordio, Gerardo Rosati, A. Tagliagambe, Salvatore Artale, Paola Rosetti, Sara Lonardi, Luca Boni, L. Cionini, on behalf of STAR Network Investigators
Journal of Clinical Oncology. 2009106 Citations
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang‐Shu Ou, Jeffrey P. Meyers, Qian Shi, Axel Grothey, Mark Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels Henrik Holländer, Fabio Galli, Kentaro Yamazaki, Vassilis Georgoulias, Rachel Kerr, Eiji Oki, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul
Journal of Clinical Oncology. 2021104 CitationsOPEN ACCESS
Related on ScholarIQ
Ospedale San Carlo
Institution
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
Paper
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
Paper
Lapatinib in breast cancer
Paper
Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
Paper
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
Paper